Company Information
Sawai Pharmaceuticals Generics Company Intelligence Report
Company Intelligence Report
| Publication Date | March 2009 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 10 |
| ISBN Number | not applicable |
| Product Code | ESP00713 |
Price
£195.00
approximately: $295 | €218
approximately: $295 | €218
Order above formats by FAX
Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Contents
- Executive Summary
- Introduction
- Products
- Leading Sawai Generics, 2002-07
- New government supply rules, 2006
- Heparin calcium, flutazolam, biperiden hydrochloride
- Synthetic penicillin
- Financial results
- Latest interim results - first nine months FY09
- Sawai Pharmaceutical: results for nine months ended 31st December 2008 in millions and US$ millions
- Latest fiscal year results, FY2008
- Sawai Pharmaceutical: Full Year Results, Fiscal year to 31st March in yen millions
- Sawai Pharmaceutical: Full Year Results, Fiscal year to 31st March in US$ millions
- Sales by Therapeutic Category, in Yen millions
- Sales by Therapeutic Category, in US$ millions
- Major developments
- Mergers, acquisitions and agreements
- Towa, Sawai and Nichi-iko sign agreement for stable supply of generic products
- Medisa Shinyaku
- Nihon Schering's Mobara factory
- Litigation
- Daiichi Sankyo files patent infringement lawsuits over levofloxacin generics
- Contact Details
